Menarini Stemline

News

AbbVie's Immunogen buy delivers rare cancer drug approval

AbbVie's Decnupaz approval will give patients with rare blood cancer BPDCN an alternative to Stemline's Elzonris with a simpler dosing regimen.

Oncology

12 Questions with Rick Coope

Rick Coope is General Manager at Menarini Stemline UK, Ireland, and the Nordics.

News

NICE backs wider NHS use of multiple myeloma drug Nexpovio

More than 1,000 people with incurable blood cancer multiple myeloma could be eligible for treatment with Menarini Stemline UK’s Nexpovio after NICE backed NHS use of the d

AbbVie's Immunogen buy delivers rare cancer drug approval

12 Questions with Rick Coope

NICE backs wider NHS use of multiple myeloma drug Nexpovio

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks